{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:54:01Z","timestamp":1791424441452,"version":"4.3.3"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T00:00:00Z","timestamp":1399507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00415-014-7366-z","type":"journal-article","created":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T06:39:04Z","timestamp":1399444744000},"page":"1234-1243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cerebrospinal fluid analysis in Alzheimer\u2019s disease: technical issues and future developments"],"prefix":"10.1007","volume":"261","author":[{"given":"Simone","family":"Lista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,8]]},"reference":[{"key":"7366_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403","journal-title":"Lancet"},{"key":"7366_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"7366_CR3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","volume":"101","author":"DM Walsh","year":"2007","unstructured":"Walsh DM, Selkoe DJ (2007) A beta oligomers\u2013\u2013a decade of discovery. J Neurochem 101:1172\u20131184","journal-title":"J Neurochem"},{"key":"7366_CR4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Alzheimer\u2019s Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R, Semagacestat Study Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","journal-title":"N Engl J Med"},{"key":"7366_CR5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:322\u2013333","journal-title":"N Engl J Med"},{"key":"7366_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer\u2019s Disease Cooperative Study Steering Committee, Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:311\u2013321","journal-title":"N Engl J Med"},{"key":"7366_CR7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrneurol.2012.202","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel H, Lista S (2012) Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 8:598\u2013600","journal-title":"Nat Rev Neurol"},{"key":"7366_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/alzrt213","volume":"5","author":"KL Moulder","year":"2013","unstructured":"Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC (2013) Dominantly Inherited Alzheimer network: facilitating research and clinical trials. Alzheimers Res Ther 5:48","journal-title":"Alzheimers Res Ther"},{"key":"7366_CR9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O\u2019brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734\u2013746","journal-title":"Lancet Neurol"},{"key":"7366_CR10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol 9:1118\u20131127","journal-title":"Lancet Neurol"},{"key":"7366_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131\u2013144","journal-title":"Nat Rev Neurol"},{"key":"7366_CR12","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jalz.2013.05.1769","volume":"9","author":"MW Weiner","year":"2013","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer\u2019s Disease Neuroimaging Initiative (2013) The Alzheimer\u2019s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement 9:e111\u2013e194","journal-title":"Alzheimers Dement"},{"key":"7366_CR13","author":"S Lista","year":"2013","unstructured":"Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H (2013) CSF A\u03b21-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer\u2019s disease. Alzheimers Dement. doi: 10.1016\/j.jalz.2013.04.506","journal-title":"Alzheimers Dement"},{"key":"7366_CR14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-clinpsy-050212-185535","volume":"9","author":"SL Risacher","year":"2013","unstructured":"Risacher SL, Saykin AJ (2013) Neuroimaging and other biomarkers for Alzheimer\u2019s disease: the changing landscape of early detection. Annu Rev Clin Psychol 9:621\u2013648","journal-title":"Annu Rev Clin Psychol"},{"key":"7366_CR15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","volume":"8","author":"MW Weiner","year":"2012","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer\u2019s Disease Neuroimaging Initiative (2012) The Alzheimer\u2019s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement 8:S1\u2013S68","journal-title":"Alzheimers Dement"},{"key":"7366_CR16","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging 27:1372\u20131384","journal-title":"Neurobiol Aging"},{"key":"7366_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S1041610298005110","volume":"10","author":"P Davidsson","year":"1998","unstructured":"Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer\u2019s disease. Int Psychogeriatr 10:11\u201323","journal-title":"Int Psychogeriatr"},{"key":"7366_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02815094","volume":"27","author":"P Davidsson","year":"1996","unstructured":"Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol 27:195\u2013210","journal-title":"Mol Chem Neuropathol"},{"key":"7366_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","volume":"20","author":"P Davidsson","year":"1999","unstructured":"Davidsson P, Puchades M, Blennow K (1999) Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis 20:431\u2013437","journal-title":"Electrophoresis"},{"key":"7366_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res 1362:13\u201322","journal-title":"Brain Res"},{"key":"7366_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1021\/pr070501k","volume":"7","author":"A Zougman","year":"2008","unstructured":"Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C, Mann M (2008) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7:386\u2013399","journal-title":"J Proteome Res"},{"key":"7366_CR22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28:595\u2013599","journal-title":"Nat Biotechnol"},{"key":"7366_CR23","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A (2014) A sensitive a\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci 34:2884\u20132897","journal-title":"J Neurosci"},{"key":"7366_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368:117\u2013127","journal-title":"N Engl J Med"},{"key":"7366_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med 368:107\u2013116","journal-title":"N Engl J Med"},{"key":"7366_CR26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","volume":"13","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, M\u00e5nsson JE, Johansson JO, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H (2011) Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13:151\u2013159","journal-title":"Neuromolecular Med"},{"key":"7366_CR27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D\u2019Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry 68:903\u2013912","journal-title":"Biol Psychiatry"},{"key":"7366_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nbd.2013.09.018","volume":"62","author":"E Barone","year":"2014","unstructured":"Barone E, Di Domenico F, Mancuso C, Butterfield DA (2014) The Janus face of the heme oxygenase\/biliverdin reductase system in Alzheimer disease: it\u2019s time for reconciliation. Neurobiol Dis 62:144\u2013159","journal-title":"Neurobiol Dis"},{"key":"7366_CR29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.52.3.562","volume":"52","author":"TJ Montine","year":"1999","unstructured":"Montine TJ, Beal MF, Cudkowicz ME, O\u2019Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562\u2013565","journal-title":"Neurology"},{"issue":"3","key":"7366_CR30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","volume":"44","author":"TJ Montine","year":"1998","unstructured":"Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer\u2019s disease. Ann Neurol 44(3):410\u2013413","journal-title":"Ann Neurol"},{"key":"7366_CR31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/ars.2005.7.269","volume":"7","author":"TJ Montine","year":"2005","unstructured":"Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD (2005) F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7:269\u2013275","journal-title":"Antioxid Redox Signal"},{"key":"7366_CR32","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00415-007-0610-z","volume":"254","author":"MJ Leon de","year":"2007","unstructured":"de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D (2007) Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 254:1666\u20131675","journal-title":"J Neurol"},{"key":"7366_CR33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/01.wnl.0000303973.71803.81","volume":"71","author":"JM Ringman","year":"2008","unstructured":"Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71:85\u201392","journal-title":"Neurology"},{"key":"7366_CR34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, H\u00e5kan W, Decraemer H, N\u00e5gga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol 69:1445\u20131452","journal-title":"Arch Neurol"},{"key":"7366_CR35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ene.12326","volume":"21","author":"H Zetterberg","year":"2014","unstructured":"Zetterberg H, Petzold M, Magdalinou N (2014) Cerebrospinal fluid alpha-synuclein levels in Parkinson\u2019s disease\u2013\u2013changed or unchanged? Eur J Neurol 21:365\u2013367","journal-title":"Eur J Neurol"},{"key":"7366_CR36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/17482968.2010.541263","volume":"12","author":"Y Noto","year":"2011","unstructured":"Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, Mori M, Uchiyama T, Isose S, Nasu S, Sekiguchi Y, Fujimaki Y, Kasai T, Tokuda T, Nakagawa M, Kuwabara S (2011) Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler 12:140\u2013143","journal-title":"Amyotroph Lateral Scler"},{"key":"7366_CR37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.pneurobio.2011.08.011","volume":"95","author":"F Geser","year":"2011","unstructured":"Geser F, Prvulovic D, O\u2019Dwyer L, Hardiman O, Bede P, Bokde AL, Trojanowski JQ, Hampel H (2011) On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol 95:649\u2013662","journal-title":"Prog Neurobiol"},{"key":"7366_CR38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89\u201395","journal-title":"Clin Pharmacol Ther"},{"key":"7366_CR39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/YCO.0b013e32835f6747","volume":"26","author":"C Ros\u00e9n","year":"2013","unstructured":"Ros\u00e9n C, Zetterberg H (2013) Cerebrospinal fluid biomarkers for pathological processes in Alzheimer\u2019s disease. Curr Opin Psychiatry 26:276\u2013282","journal-title":"Curr Opin Psychiatry"},{"issue":"Suppl 1","key":"7366_CR40","first-page":"S361","volume":"33","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Blennow K (2013) Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: more to come? J Alzheimers Dis 33(Suppl 1):S361\u2013S369","journal-title":"J Alzheimers Dis"},{"key":"7366_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2013.205","volume":"95","author":"J Cummings","year":"2014","unstructured":"Cummings J, Zhong K (2014) Biomarker-driven therapeutic management of Alzheimer\u2019s disease: establishing the foundations. Clin Pharmacol Ther 95:67\u201377","journal-title":"Clin Pharmacol Ther"},{"key":"7366_CR42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer\u2019s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8:312\u2013336","journal-title":"Alzheimers Dement"},{"key":"7366_CR43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-8-20","volume":"8","author":"C Ros\u00e9n","year":"2013","unstructured":"Ros\u00e9n C, Hansson O, Blennow K, Zetterberg H (2013) Fluid biomarkers in Alzheimer\u2019s disease\u2013\u2013current concepts. Mol Neurodegener 8:20","journal-title":"Mol Neurodegener"},{"key":"7366_CR44","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1373\/clinchem.2013.202937","volume":"59","author":"JH Kang","year":"2013","unstructured":"Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM (2013) Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-\u03b2(1-42) and \u03c4 proteins as Alzheimer disease biomarkers. Clin Chem 59:903\u2013916","journal-title":"Clin Chem"},{"key":"7366_CR45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/bmm.12.44","volume":"6","author":"U Andreasson","year":"2012","unstructured":"Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H (2012) Analytical aspects of molecular Alzheimer\u2019s disease biomarkers. Biomark Med 6:377\u2013389","journal-title":"Biomark Med"},{"key":"7366_CR46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/bmm.12.39","volume":"6","author":"N Mattsson","year":"2012","unstructured":"Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E (2012) Reference measurement procedures for Alzheimer\u2019s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid \u03b242. Biomark Med 6:409\u2013417","journal-title":"Biomark Med"},{"issue":"Suppl 2","key":"7366_CR47","first-page":"S116","volume":"13","author":"PR Wattamwar","year":"2010","unstructured":"Wattamwar PR, Mathuranath PS (2010) An overview of biomarkers in Alzheimer\u2019s disease. Ann Indian Acad Neurol 13(Suppl 2):S116\u2013S123","journal-title":"Ann Indian Acad Neurol"},{"key":"7366_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1373\/clinchem.2004.044016","volume":"51","author":"BB Miller","year":"2005","unstructured":"Miller BB, Mandell JW (2005) Multiplex method for measuring biomarkers of Alzheimer disease in cerebrospinal fluid. Clin Chem 51:289\u2013290","journal-title":"Clin Chem"},{"key":"7366_CR49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ymeth.2012.03.023","volume":"56","author":"JH Kang","year":"2012","unstructured":"Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer\u2019s disease. Methods 56:484\u2013493","journal-title":"Methods"},{"key":"7366_CR50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O (2013) Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther 5:9","journal-title":"Alzheimers Res Ther"},{"key":"7366_CR51","doi-asserted-by":"crossref","first-page":"e28263","DOI":"10.1371\/journal.pone.0028263","volume":"6","author":"H Zetterberg","year":"2011","unstructured":"Zetterberg H, M\u00f6rtberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG, Meyer R, Rivnak AJ, Pink BA, Minnehan KA, Piech T, Rissin DM, Duffy DC, Rubertsson S, Wilson DH, Blennow K (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid \u03b2 levels in humans. PLoS One 6:e28263","journal-title":"PLoS One"},{"key":"7366_CR52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3233\/JAD-2012-121471","volume":"33","author":"J Pannee","year":"2013","unstructured":"Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, H\u00f6jrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J (2013) A selected reaction monitoring (SRM)-based method for absolute quantification of A\u03b238, A\u03b240, and A\u03b242 in cerebrospinal fluid of Alzheimer\u2019s disease patients and healthy controls. J Alzheimers Dis 33:1021\u20131032","journal-title":"J Alzheimers Dis"},{"issue":"M111","key":"7366_CR53","first-page":"013987","volume":"11","author":"C Ludwig","year":"2012","unstructured":"Ludwig C, Claassen M, Schmidt A, Aebersold R (2012) Estimation of absolute protein quantities of unlabeled samples by selected reaction monitoring mass spectrometry. Mol Cell Proteomics 11(M111):013987","journal-title":"Mol Cell Proteomics"},{"key":"7366_CR54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nmeth.2015","volume":"9","author":"P Picotti","year":"2012","unstructured":"Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9:555\u2013566","journal-title":"Nat Methods"},{"key":"7366_CR55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-biochem-072909-100424","volume":"81","author":"A Bensimon","year":"2012","unstructured":"Bensimon A, Heck AJ, Aebersold R (2012) Mass spectrometry-based proteomics and network biology. Annu Rev Biochem 81:379\u2013405","journal-title":"Annu Rev Biochem"},{"key":"7366_CR56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.copbio.2011.11.014","volume":"23","author":"E Sabid\u00f3","year":"2012","unstructured":"Sabid\u00f3 E, Selevsek N, Aebersold R (2012) Mass spectrometry-based proteomics for systems biology. Curr Opin Biotechnol 23:591\u2013597","journal-title":"Curr Opin Biotechnol"},{"key":"7366_CR57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tins.2008.10.003","volume":"32","author":"F Noorbakhsh","year":"2009","unstructured":"Noorbakhsh F, Overall CM, Power C (2009) Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 32:88\u2013100","journal-title":"Trends Neurosci"},{"key":"7366_CR58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nature01510","volume":"422","author":"M Tyers","year":"2003","unstructured":"Tyers M, Mann M (2003) From genomics to proteomics. Nature 422:193\u2013197","journal-title":"Nature"},{"key":"7366_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14789450.2.1.1","volume":"2","author":"M Hamacher","year":"2005","unstructured":"Hamacher M, Meyer HE (2005) HUPO Brain Proteome Project: aims and needs in proteomics. Expert Rev Proteomics 2:1\u20133","journal-title":"Expert Rev Proteomics"},{"key":"7366_CR60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","volume":"422","author":"R Aebersold","year":"2003","unstructured":"Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198\u2013207","journal-title":"Nature"},{"key":"7366_CR61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000334537","volume":"10","author":"E Portelius","year":"2012","unstructured":"Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K (2012) Evaluation of the performance of novel A\u03b2 isoforms as theragnostic markers in Alzheimer\u2019s disease: from the cell to the patient. Neurodegener Dis 10:138\u2013140","journal-title":"Neurodegener Dis"},{"key":"7366_CR62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","volume":"32","author":"E Portelius","year":"2011","unstructured":"Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090\u20131098","journal-title":"Neurobiol Aging"},{"key":"7366_CR63","doi-asserted-by":"crossref","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease. PLoS One 6:e16032","journal-title":"PLoS One"},{"key":"7366_CR64","doi-asserted-by":"crossref","first-page":"e18850","DOI":"10.1371\/journal.pone.0018850","volume":"6","author":"R Craig-Schapiro","year":"2011","unstructured":"Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer\u2019s disease diagnosis and prognosis. PLoS One 6:e18850","journal-title":"PLoS One"},{"key":"7366_CR65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt30","volume":"2","author":"E Portelius","year":"2010","unstructured":"Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2:7","journal-title":"Alzheimers Res Ther"},{"key":"7366_CR66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/prca.200900166","volume":"4","author":"V Albertini","year":"2010","unstructured":"Albertini V, Bruno A, Paterlini A, Lista S, Benussi L, Cereda C, Binetti G, Ghidoni R (2010) Optimization protocol for amyloid-\u03b2 peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 4:352\u2013357","journal-title":"Proteomics Clin Appl"},{"key":"7366_CR67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000203774","volume":"6","author":"E Portelius","year":"2009","unstructured":"Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K (2009) Identification of novel APP\/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 6:87\u201394","journal-title":"Neurodegener Dis"},{"key":"7366_CR68","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.neurobiolaging.2007.01.011","volume":"29","author":"AH Simonsen","year":"2008","unstructured":"Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. Neurobiol Aging 29:961\u2013968","journal-title":"Neurobiol Aging"},{"key":"7366_CR69","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archneur.64.3.366","volume":"64","author":"AH Simonsen","year":"2007","unstructured":"Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64:366\u2013370","journal-title":"Arch Neurol"},{"key":"7366_CR70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000110576","volume":"24","author":"AH Simonsen","year":"2007","unstructured":"Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, Vassilopoulos D, Waldemar G (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer\u2019s disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24:434\u2013440","journal-title":"Dement Geriatr Cogn Disord"},{"key":"7366_CR71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.21038","volume":"61","author":"EJ Finehout","year":"2007","unstructured":"Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer\u2019s disease. Ann Neurol 61:120\u2013129","journal-title":"Ann Neurol"},{"key":"7366_CR72","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"6","author":"E Portelius","year":"2007","unstructured":"Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6:4433\u20134439","journal-title":"J Proteome Res"},{"key":"7366_CR73","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/prca.200600999","volume":"1","author":"Y Hu","year":"2007","unstructured":"Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer\u2019s disease. Proteomics Clin Appl 1:1373\u20131384","journal-title":"Proteomics Clin Appl"},{"key":"7366_CR74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neulet.2006.09.044","volume":"409","author":"E Portelius","year":"2006","unstructured":"Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K (2006) An Alzheimer\u2019s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409:215\u2013219","journal-title":"Neurosci Lett"},{"key":"7366_CR75","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/pr050475v","volume":"5","author":"E Portelius","year":"2006","unstructured":"Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 5:1010\u20131016","journal-title":"J Proteome Res"},{"key":"7366_CR76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","volume":"9","author":"F Abdi","year":"2006","unstructured":"Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293\u2013348","journal-title":"J Alzheimers Dis"},{"key":"7366_CR77","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/138620705774962391","volume":"8","author":"H Selle","year":"2005","unstructured":"Selle H, Lamerz J, Buerger K, Dessauer A, Hager K, Hampel H, Karl J, Kellmann M, Lannfelt L, Louhija J, Riepe M, Rollinger W, Tumani H, Schrader M, Zucht HD (2005) Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer\u2019s disease. Comb Chem High Throughput Screen 8:801\u2013806","journal-title":"Comb Chem High Throughput Screen"},{"key":"7366_CR78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-2005-7205","volume":"7","author":"J Zhang","year":"2005","unstructured":"Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7:125\u2013133","journal-title":"J Alzheimers Dis"},{"key":"7366_CR79","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pmic.200300470","volume":"3","author":"O Carrette","year":"2003","unstructured":"Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer\u2019s disease. Proteomics 3:1486\u20131494","journal-title":"Proteomics"},{"key":"7366_CR80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","volume":"118","author":"M Puchades","year":"2003","unstructured":"Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer\u2019s disease. Brain Res Mol Brain Res 118:140\u2013146","journal-title":"Brain Res Mol Brain Res"},{"key":"7366_CR81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00001756-200204160-00015","volume":"13","author":"P Davidsson","year":"2002","unstructured":"Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, Sj\u00f6gren M, Blennow K (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport 13:611\u2013615","journal-title":"NeuroReport"},{"key":"7366_CR82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/pmic.200600756","volume":"7","author":"S Pan","year":"2007","unstructured":"Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J (2007) A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7:469\u2013473","journal-title":"Proteomics"},{"key":"7366_CR83","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nbt1235","volume":"24","author":"N Rifai","year":"2006","unstructured":"Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971\u2013983","journal-title":"Nat Biotechnol"},{"key":"7366_CR84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Biomark Med 6:455\u2013476","journal-title":"Biomark Med"},{"key":"7366_CR85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.12703\/P5-18","volume":"5","author":"ME Dumas","year":"2013","unstructured":"Dumas ME, Davidovic L (2013) Metabolic phenotyping and systems biology approaches to understanding neurological disorders. F1000Prime Rep 5:18","journal-title":"F1000Prime Rep"},{"key":"7366_CR86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/gm339","volume":"4","author":"TD Veenstra","year":"2012","unstructured":"Veenstra TD (2012) Metabolomics: the final frontier? Genome Med 4:40","journal-title":"Genome Med"},{"key":"7366_CR87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11708","volume":"491","author":"JK Nicholson","year":"2012","unstructured":"Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC (2012) Metabolic phenotyping in clinical and surgical environments. Nature 491:384\u2013392","journal-title":"Nature"},{"key":"7366_CR88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/gm337","volume":"4","author":"R Mandal","year":"2012","unstructured":"Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, Aziat F, Wishart DS (2012) Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med 4:38","journal-title":"Genome Med"},{"key":"7366_CR89","author":"E Trushina","year":"2013","unstructured":"Trushina E, Mielke MM (2013) Recent advances in the application of metabolomics to Alzheimer\u2019s disease. Biochim Biophys Acta. doi: 10.1016\/j.bbadis.2013.06.014","journal-title":"Biochim Biophys Acta"},{"key":"7366_CR90","doi-asserted-by":"crossref","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics. PLoS One 8:e63644","journal-title":"PLoS One"},{"key":"7366_CR91","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1038\/tp.2013.18","volume":"3","author":"R Kaddurah-Daouk","year":"2013","unstructured":"Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE, Pharmacometabolomics Research Network (2013) Alterations in metabolic pathways and networks in Alzheimer\u2019s disease. Transl Psychiatry 3:e244","journal-title":"Transl Psychiatry"},{"key":"7366_CR92","doi-asserted-by":"crossref","first-page":"e31501","DOI":"10.1371\/journal.pone.0031501","volume":"7","author":"C Czech","year":"2012","unstructured":"Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, Hampel H, Kastler J, Senn H (2012) Metabolite profiling of Alzheimer\u2019s disease cerebrospinal fluid. PLoS One 7:e31501","journal-title":"PLoS One"},{"key":"7366_CR93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jalz.2010.06.001","volume":"7","author":"R Kaddurah-Daouk","year":"2011","unstructured":"Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-Bohmer KA (2011) Metabolomic changes in autopsy-confirmed Alzheimer\u2019s disease. Alzheimers Dement 7:309\u2013317","journal-title":"Alzheimers Dement"},{"key":"7366_CR94","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cell.2010.11.033","volume":"143","author":"MR Wenk","year":"2010","unstructured":"Wenk MR (2010) Lipidomics: new tools and applications. Cell 143:888\u2013895","journal-title":"Cell"},{"key":"7366_CR95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.plefa.2011.04.021","volume":"85","author":"G Astarita","year":"2011","unstructured":"Astarita G, Piomelli D (2011) Towards a whole-body systems [multi-organ] lipidomics in Alzheimer\u2019s disease. Prostaglandins Leukot Essent Fatty Acids 85:197\u2013203","journal-title":"Prostaglandins Leukot Essent Fatty Acids"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-014-7366-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7366-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T07:53:57Z","timestamp":1565423637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-014-7366-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,8]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["7366"],"URL":"https:\/\/doi.org\/10.1007\/s00415-014-7366-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,8]]}}}